stoxline Quote Chart Rank Option Currency Glossary
  
Evaxion Biotech A/S (EVAX)
2.54  -0.13 (-4.87%)    07-15 16:00
Open: 2.66
High: 2.66
Volume: 34,372
  
Pre. Close: 2.67
Low: 2.54
Market Cap: 16(M)
Technical analysis
2025-07-15 3:47:01 PM
Short term     
Mid term     
Targets 6-month :  3.22 1-year :  3.72
Resists First :  2.76 Second :  3.19
Pivot price 2.5
Supports First :  2.06 Second :  1.72
MAs MA(5) :  2.59 MA(20) :  2.45
MA(100) :  2 MA(250) :  6.93
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  54.1 D(3) :  56.8
RSI RSI(14): 52.8
52-week High :  17.75 Low :  1.2
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ EVAX ] has closed below upper band by 42.0%. Bollinger Bands are 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.8 - 2.81 2.81 - 2.82
Low: 2.52 - 2.53 2.53 - 2.54
Close: 2.65 - 2.67 2.67 - 2.68
Company Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Headline News

Fri, 23 May 2025
Evaxion A/S to Announce Q1 2025 Financial Results and Business Update - TipRanks

Mon, 28 Apr 2025
AI-Powered Cancer Vaccine Shows Breakthrough 80% Success Rate in Advanced Melanoma Trial - Stock Titan

Tue, 25 Mar 2025
Groundbreaking AI Cancer Vaccine Shows Promise: Phase 2 Data Reveals Critical Insights - Stock Titan

Tue, 25 Feb 2025
Evaxion's Cancer Vaccine Shows 69% Response Rate, Trial Extended - Stock Titan

Mon, 30 Dec 2024
Evaxion Biotech Announces 1:5 ADS Ratio Change, Effective January 2025 - Stock Titan

Mon, 09 Dec 2024
Evaxion Biotech Unveils Ambitious 2025 Roadmap: AI-Powered Vaccines, $10M Deal Potential, Clinical Milestones - Stock Titan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 6 (M)
Shares Float 155 (M)
Held by Insiders 23 (%)
Held by Institutions 7 (%)
Shares Short 50 (K)
Shares Short P.Month 12 (K)
Stock Financials
EPS -12
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.87
Profit Margin 0 %
Operating Margin -431.4 %
Return on Assets (ttm) -37.1 %
Return on Equity (ttm) -206.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0.52
Sales Per Share 0.52
EBITDA (p.s.) -2.19
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -0.22
PEG Ratio 0
Price to Book value 1.35
Price to Sales 4.87
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android